Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M

Outset Medical, Inc.

2025-Q2 EPS reported -$3.57 revenue$61,171,000

Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).
Non-GAAP gross margin 38.4% (+110bps); operating expenses down 29% YoY; net loss $18.5M vs $34.5M.
Raised 2025 revenue guidance to $122-126M from $115-125M; expects <$50M cash use vs >$100M in 2024.
New enterprise agreement with large national health system; Tablo now in >900 U.S. acute/sub-acute sites.
Cash $187.4M at June 30; H1 cash burn reduced ~60% vs prior year.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.